PCSK9 GWAS
The GWAS study (genome-wide association study) of PCSK9 plasma levels authored by Pott et al 4 in this issue of the Circulation: Genomic and Precision Medicine Journal identified 5 independent genetic variants at genome-wide significance as well as 7 suggestive loci associated with plasma PCSK9. This GWAS study was conducted using the data from the LIFE-Heart (Leipzig Research Centre for Civilization Diseases Heart Study) cohort that comprise 3290 individuals with suspected and confirmed coronary artery disease. The authors found that the PCSK9 locus represents the strongest genetic predictor of circulating PCSK9. Indeed, 4 independent PCSK9 single nucleotide polymorphisms explained 4.4% of the variance of PCSK9 levels. Another genome-wide significant variant was found on the chromosome 7, in the FBXL18 gene. In addition, in their Mendelian randomization study, the authors' data suggest a causal effect of PCSK9 on the presence and the severity of the atherosclerotic vascular disease.
This study represents the first GWAS of plasma PCSK9 levels to identify genome-wide significant loci. Indeed, in the previous GWAS of Chernogubova et al, 5 the authors did not detect genome-wide significant variants but identified several suggestive PCSK9 single nucleotide polymorphisms associated with PCSK9 concentration. However, their discovery cohort was relatively small (n=1215). Furthermore, the chromosome 7 variant of FBXL18 was not identified in this previous study.
WHAT IS KNOWN ABOUT THE 7P22.1 CHROMOSOMIC REGION?
Interestingly, Pott et al 4 discovered one genome-wide significant variant associated with plasma PCSK9 levels that is not located in the PCSK9 gene. This single nucleotide polymorphism (rs6957201) is located in the 7p22.1 region within the FBXL18 gene. Little is known about this chromosomic region. To date, mutations in 7p22 have been associated with disorders such as autism and familial hyperaldosteronism.
6-8 Microdeletions of 7p22.1 have been associated with developmental delay, short stature, and microcephaly, 9 whereas microduplications have been associated with a condition called the 7p22.1 microduplication syndrome. 10 It would be interesting to further investigate the link between this genetic region and plasma PCSK9 and LDL-C levels. This association, however, warrant independent validation, particularly because of the low imputation quality reported by the authors for this single nucleotide polymorphism.
WHY ARE THESE RESULTS IMPORTANT?
There exists considerable interindividual variation in plasma PCSK9 levels. Indeed, Lakoski et al, 11 found that circulating PCSK9 varied over a 100-fold range in a large multiethnic cohort. They also showed that only 20% of circulating PCSK9 variance would be explained by clinical variables such as age, sex, menopausal status, body habitus, and circulating indices of lipid and glucose metabolism. 11 However, little is known about genetic factors that contribute to this variability. Identifying novel loci associated with PCSK9 concentrations could perhaps help with the identification of proteins interacting with PCSK9 and these novel loci could offer insights for the development of novel therapies modulating circulating PCSK9. Furthermore, the identification of loci associated with PCSK9 concentration could help to understand the potential extrahepatic functions of PCSK9. It has been suggested that PCSK9 may play a role in the transintestinal cholesterol excretion and perhaps in the regulation of pancreatic homeostasis, although other functions remain to be discovered.
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IS PLASMA PCSK9 A POTENTIAL BIOMARKER FOR CVD RISK STRATIFICATION?
The usefulness of circulating PCSK9 as a biomarker for CVD risk has not yet been proven. Interestingly, besides its role in LDLR metabolism, plasma PCSK9 levels have been associated with the diagnosis of metabolic syndrome as well as individual metabolic syndrome traits. Therefore, it would be important to explore whether PCSK9 could represent a potential biomarker of metabolic syndrome.
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CONCLUSIONS
Pott et al 4 have identified a variant of the chromosome 7 in the FBXL18 gene as a potential modulator of PCSK9. Further research is needed to validate this association in independent cohorts. Furthermore, the mechanism by which FBXL18 may modulate PCSK9 remains unknown, and it remains to be determined whether this locus affects the synthesis, the stability, or the degradation of PCSK9. 
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